Article
Positron Emission Tomography/Computed Tomography Imaging with [18F]PARPi for Precision Guidance of Poly ADP-ribose Polymerase Inhibitor Therapy in Homologous Recombination Repair Mutated and Nonmutated Metastatic Castration-resistant Prostate Cancer.
European urology oncology - 1 Jun 2026
Ofner Heidemarie, Einspieler Holger, Ozenil Marius, Spielvogel Clemens P, Langrate Ilva Kristiana, Bamminger Karsten, Hassler Melanie R, Baltzer Pascal A T, Shariat Shahrokh F, Hacker Marcus, Rasul Sazan, Kramer Gero
Abstract excerpt
BACKGROUND AND OBJECTIVE: Poly ADP-ribose polymerase (PARP) inhibitors have become an important treatment option for metastatic castration-resistant prostate cancer (mCRPC), targeting PARP1-mediated DNA repair. We investigated [18F]PARPi positron emission tomography (PET) uptake as a predictive biomarker of mCRPC. METHODS: We retrospectively analyzed 15 mCRPC patients who underwent [18F]PARPi PET/computed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.